NICE backs Humira, Enbrel and Stelara for plaque psoriasis in children

AbbVie’s Humira, Pfizer’s Enbrel, and Janssen’s Stelara are being recommended as options for treating plaque psoriasis in children and young people on the NHS. The National Institute for Health and Care Excellence has now published final guidance backing all three drugs as options for children and young people, according to their age, whose psoriasis is severe and has not improved with other treatments or they can’t be used. It also stipulates that treatment with Enbrel (etanercept) should be stopped at 12 weeks, and with Humira (adalimumab) and Stelara (ustekinumab) at 16 weeks, if the psoriasis has not responded adequately (defined as a 75 percent reduction in the PASI score from the start of treatment).